middle.news
Patrys Abandons PAT-DX1 Trial Plans, Accelerates PAT-DX3 Development
8:45am on Thursday 30th of January, 2025 AEDT
•
Biotechnology
Read Story
Patrys Abandons PAT-DX1 Trial Plans, Accelerates PAT-DX3 Development
8:45am on Thursday 30th of January, 2025 AEDT
Key Points
PAT-DX1 drug material fails specification testing, unsuitable for Phase 1 trial
Strategic pivot to develop PAT-DX3 targeting inflammatory diseases via NETosis inhibition
Cost reduction measures implemented to preserve cash reserves
Received $1.3 million R&D tax incentive rebate for FY2023/24
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE